| Central Venous Catheters and Hemodialysis | Lifetime | 1 | AU 1 | 99.95 |
| Dialysis and Renal Disease Management | Lifetime | 7 | AU 1 | 99.93 |
| Muscle and Compartmental Disorders | Lifetime | 6 | AU 2 | 99.75 |
| Renal and Vascular Pathologies | Lifetime | 22 | AU 1 | 99.66 |
| Metabolism and Genetic Disorders | Lifetime | 65 | AU 2 | 99.52 |
| Chronic Kidney Disease and Diabetes | Lifetime | 36 | AU 3 | 99.69 |
| Acute Kidney Injury Research | Lifetime | 30 | AU 2 | 99.41 |
| Renal Transplantation Outcomes and Treatments | Lifetime | 85 | AU 6 | 99.41 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 176 | AU 5 | 99.41 |
| Erythropoietin and Anemia Treatment | Lifetime | 28 | AU 1 | 99.24 |
| Iron Metabolism and Disorders | Lifetime | 151 | AU 7 | 98.67 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 230 | AU 4 | 98.52 |
| Healthcare cost, quality, practices | Lifetime | 85 | AU 4 | 98.43 |
| Potassium and Related Disorders | Lifetime | 63 | AU 1 | 98.59 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 374 | AU 22 | 98.09 |
| Renal Diseases and Glomerulopathies | Lifetime | 358 | AU 10 | 98.20 |
| Parathyroid Disorders and Treatments | Lifetime | 283 | AU 5 | 98.06 |
| Otolaryngology and Infectious Diseases | Lifetime | 53 | AU 5 | 96.97 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 362 | AU 8 | 97.46 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 563 | AU 23 | 97.54 |
| Blood Pressure and Hypertension Studies | Lifetime | 759 | AU 47 | 97.92 |
| Kidney Stones and Urolithiasis Treatments | Lifetime | 302 | AU 5 | 96.96 |
| Heart Failure Treatment and Management | Lifetime | 797 | AU 20 | 97.28 |
| Organ Donation and Transplantation | Lifetime | 449 | AU 22 | 96.82 |
| Renal function and acid-base balance | Lifetime | 488 | AU 19 | 95.49 |
| Neurological Complications and Syndromes | Lifetime | 304 | AU 12 | 95.07 |
| Thermal and Kinetic Analysis | Lifetime | 836 | AU 15 | 94.81 |
| Genetic and Kidney Cyst Diseases | Lifetime | 518 | AU 8 | 93.94 |
| Polyomavirus and related diseases | Lifetime | 846 | AU 29 | 94.22 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 438 | AU 14 | 92.75 |
| Bullying, Victimization, and Aggression | Lifetime | 470 | AU 15 | 93.84 |
| Biomedical Research and Pathophysiology | Lifetime | 417 | AU 8 | 91.78 |
| Youth Development and Social Support | Lifetime | 611 | AU 40 | 91.58 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 210 | AU 7 | 87.06 |
| Vascular Anomalies and Treatments | Lifetime | 640 | AU 9 | 86.83 |
| Magnesium in Health and Disease | Lifetime | 781 | AU 15 | 84.60 |
| Leptospirosis research and findings | Lifetime | 976 | AU 49 | 79.52 |
| Education Discipline and Inequality | Lifetime | 477 | AU 8 | 76.86 |
| Psychological and Educational Research Studies | Lifetime | 350 | AU 19 | 65.90 |
| Cognitive and psychological constructs research | Lifetime | 548 | AU 22 | 62.08 |
| Environmental Monitoring and Data Management | Lifetime | 797 | AU 35 | 54.48 |
| Dialysis and Renal Disease Management | 2021-2025 | 3 | AU 1 | 99.75 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 7 | AU 3 | 99.02 |
| Renal and Vascular Pathologies | 2021-2025 | 36 | AU 1 | 97.91 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 54 | AU 4 | 98.53 |
| Renal Transplantation Outcomes and Treatments | 2021-2025 | 89 | AU 3 | 97.63 |
| Organ Donation and Transplantation | 2021-2025 | 105 | AU 3 | 95.33 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 552 | AU 59 | 95.29 |
| Acute Kidney Injury Research | 2021-2025 | 115 | AU 6 | 94.70 |
| Healthcare cost, quality, practices | 2021-2025 | 103 | AU 12 | 92.57 |
| Muscle and Compartmental Disorders | 2021-2025 | 62 | AU 3 | 89.02 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 538 | AU 7 | 90.80 |
| Potassium and Related Disorders | 2021-2025 | 131 | AU 6 | 89.18 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 624 | AU 29 | 82.97 |
| Nosocomial Infections in ICU | 2021-2025 | 437 | AU 22 | 79.30 |
| Pregnancy and Medication Impact | 2021-2025 | 676 | AU 38 | 77.57 |
| Renal function and acid-base balance | 2021-2025 | 306 | AU 16 | 71.68 |
| Neurological Complications and Syndromes | 2021-2025 | 528 | AU 8 | 62.13 |
| Electrolyte and hormonal disorders | 2021-2025 | 854 | AU 40 | 61.60 |
| Biomedical Research and Pathophysiology | 2021-2025 | 748 | AU 9 | 36.25 |
